ALMR News & Events

Alamar Biosciences priced 11.25M shares at $17.00. The deal size was increased and priced at the high-end of the range. Alamar is a life sciences company that says its platform is designed to detect biomarkers with ultra-high sensitivity and "address key limitations of existing technologies, helping researchers unlock the full spectrum of protein biomarkers across disease states."

Alamar Biosciences priced 11.25M shares at $17.00. The deal size was increased to 11.25M shares of common stock from 9.375M shares and priced at the high-end of the $15.00-$17.00 range. JPMorgan, BofA, TD Cowen, Leerink and Stifel acted as joint book running managers for the offering. Alamar is a life sciences company that says its platform is designed to detect biomarkers with ultra-high sensitivity and "address key limitations of existing technologies, helping researchers unlock the full spectrum of protein biomarkers across disease states."

The deal size was increased to 11.25M shares of common stock from 9.375M shares of common stock and priced at the high-end of the $15.00-$17.00 range. JPMorgan, BofA, TD Cowen, Leerink and Stifel acted as joint book running managers for the offering.